MabThera

Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012

...h other mechanisms of action, such as Orencia and Biogen Idec/Genentech's Rituxan (also marketed by Chugai and Zenyaku Kogyo in Japan, and marketed as mabthera in Europe by Roche), largely for TNF-alpha inadequate responders. According to the new report entitled Brands & Strategies : Rheumatoid Arthriti...

MabThera in Medical Technology

Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma

Adding MabThera to first line chemotherapy significantly increases patients_ overall survival BASEL, Switzerland (21 May, 2007) _ In a study published yesterday in the Journal of Clinical Oncology, MabThera (rituximab) plus chemotherapy (MCP*) was shown to significantly improve survival in patie...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

...e response following first-line treatment with CVP chemotherapy. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets mabthera in the rest of the world, except Japan, where Rituxan is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Rituxan has more than 1,000,000 patient expo...

Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology

...e response following first-line treatment with CVP chemotherapy. Genentech and Biogen Idec co-market Rituxan in the United States, and Roche markets mabthera in the rest of the world, except Japan, where Rituxan is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Rituxan has more than 1,000,000 patient expo...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

...ional Cancer Institute, the innovative cancer drug mabthera was shown to improve overall survival in patients ...relapsed patients involved in trials that compared mabthera treatment regimens with chemotherapy alone. The re...with MabThera but also that disease control in the mabthera containing arms of the trials was significantly su...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

... that over half (53%) of the patients treated with mabthera were still alive after seven years compared with j...bThera. The analysis also demonstrated that more mabthera treated patients were in remission at seven years ...is study clearly demonstrates that the addition of mabthera to treatment cures more patients with aggressive l...

New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis

...g the launch of MabThera® (rituximab) there are a number of projects in development, potentially allowing Roche to build on further opportunities. mabthera is the first and only selective B-cell therapy for RA, providing a fundamentally different treatment approach by targeting B cells, one of the key pla...